Login to Your Account



New 'Paradigm' in heart failure; Novartis' combo pill to have 'major impact'

By Nuala Moran
Staff Writer

Tuesday, September 2, 2014
LONDON – Novartis AG hailed the results of its Paradigm trial of LCZ696 as "a historical moment in the treatment of heart failure," with the combined ACE/neprilysin inhibitor reducing deaths by 20 percent, cutting hospitalizations by 21 percent and offering better quality of life, compared to treatment with ACE inhibitor enalapril alone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription